{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:15Z","timestamp":1707525015993},"reference-count":79,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,24]]},"DOI":"10.7759\/cureus.38085","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T03:58:13Z","timestamp":1682395093000},"source":"Crossref","is-referenced-by-count":0,"title":["The Fragile Patient: Considerations in the Management of Invasive Mould Infections (IMIs) in India"],"prefix":"10.7759","author":[{"given":"Prithwijit","family":"Kundu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: complexities and solutions","volume":"72","author":"Bassetti M","year":"2017","unstructured":"Bassetti M, Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017, 72:i39-47. 10.1093\/jac\/dkx032","journal-title":"J Antimicrob Chemother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12598","article-title":"Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Blyth CC","year":"2014","unstructured":"Blyth CC, Gilroy NM, Guy SD, et al.. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014, 44:1333-49. 10.1111\/imj.12598","journal-title":"Intern Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019737","article-title":"Treatment principles for the management of mold infections","volume":"5","author":"Kontoyiannis DP","year":"2014","unstructured":"Kontoyiannis DP, Lewis RE. Treatment principles for the management of mold infections. Cold Spring Harb Perspect Med. 2014, 5:a019737. 10.1101\/cshperspect.a019737","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1195529","article-title":"Trehalose pathway as an antifungal target","volume":"8","author":"Perfect JR","year":"2017","unstructured":"Perfect JR, Tenor JL, Miao Y, Brennan RG. Trehalose pathway as an antifungal target. Virulence. 2017, 8:143-9. 10.1080\/21505594.2016.1195529","journal-title":"Virulence"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision","volume":"3","author":"Bongomin F","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases\u2014estimate precision. J Fungi (Basel). 2017, 3:57. 10.3390\/jof3040057","journal-title":"J Fungi (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash H","year":"2019","unstructured":"Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019, 5:26. 10.3390\/jof5010026","journal-title":"J Fungi (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12243","article-title":"Mucormycosis in India: unique features","volume":"57","author":"Chakrabarti A","year":"2014","unstructured":"Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014, 57:85-90. 10.1111\/myc.12243","journal-title":"Mycoses"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-2919-6","article-title":"Serious fungal infections in Pakistan","volume":"36","author":"Jabeen K","year":"2017","unstructured":"Jabeen K, Farooqi J, Mirza S, Denning D, Zafar A. Serious fungal infections in Pakistan. Eur J Clin Microbiol Infect Dis. 2017, 36:949-56. 10.1007\/s10096-017-2919-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/20499361211027065","article-title":"COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs","volume":"8","author":"Rodriguez-Morales AJ","year":"2021","unstructured":"Rodriguez-Morales AJ, Sah R, Millan-O\u00f1ate J, et al.. COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis. 2021, 8:10.1177\/20499361211027065","journal-title":"Ther Adv Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3201\/eid2709.210934","article-title":"Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India","volume":"27","author":"Patel A","year":"2021","unstructured":"Patel A, Agarwal R, Rudramurthy SM, et al.. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021, 27:2349-59. 10.3201\/eid2709.210934","journal-title":"Emerg Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1565_21","article-title":"Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1","volume":"69","author":"Sen M","year":"2021","unstructured":"Sen M, Honavar SG, Bansal R, et al.. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol. 2021, 69:1670-92. 10.4103\/ijo.IJO_1565_21","journal-title":"Indian J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel A","year":"2020","unstructured":"Patel A, Kaur H, Xess I, et al.. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020, 26:944.e9-15. 10.1016\/j.cmi.2019.11.021","journal-title":"Clin Microbiol Infect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23387","article-title":"Mucormycosis in a tertiary care center in South India: a 4-year experience","volume":"24","author":"Priya P","year":"2020","unstructured":"Priya P, Ganesan V, Rajendran T, Geni VG. Mucormycosis in a tertiary care center in South India: a 4-year experience. Indian J Crit Care Med. 2020, 24:168-71. 10.5005\/jp-journals-10071-23387","journal-title":"Indian J Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.02.005","article-title":"Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study)","volume":"51","author":"Chakrabarti A","year":"2019","unstructured":"Chakrabarti A, Kaur H, Savio J, et al.. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care. 2019, 51:64-70. 10.1016\/j.jcrc.2019.02.005","journal-title":"J Crit Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jof4020046","article-title":"Mucormycosis: battle with the deadly enemy over a five-year period in India","volume":"4","author":"Chander J","year":"2018","unstructured":"Chander J, Kaur M, Singla N, et al.. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi (Basel). 2018, 4:46. 10.3390\/jof4020046","journal-title":"J Fungi (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myx029","article-title":"Epidemiology and clinical characteristics of invasive mould infections: a multicenter, retrospective analysis in five Asian countries","volume":"56","author":"Rotjanapan P","year":"2018","unstructured":"Rotjanapan P, Chen YC, Chakrabarti A, et al.. Epidemiology and clinical characteristics of invasive mould infections: a multicenter, retrospective analysis in five Asian countries. Med Mycol. 2018, 56:186-96. 10.1093\/mmy\/myx029","journal-title":"Med Mycol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12610","article-title":"Mucormycosis at a tertiary care centre in Gujarat, India","volume":"60","author":"Patel AK","year":"2017","unstructured":"Patel AK, Patel KK, Patel K, Gohel S, Chakrabarti A. Mucormycosis at a tertiary care centre in Gujarat, India. Mycoses. 2017, 60:407-11. 10.1111\/myc.12610","journal-title":"Mycoses"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth F","year":"2017","unstructured":"Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease. J Antimicrob Chemother. 2017, 72:i19-28. 10.1093\/jac\/dkx030","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087784","article-title":"Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing","volume":"9","author":"Nucci M","year":"2014","unstructured":"Nucci M, Carlesse F, Cappellano P, et al.. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One. 2014, 9:e87784. 10.1371\/journal.pone.0087784","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12466","article-title":"Why is mucormycosis more difficult to cure than more common mycoses?","volume":"20","author":"Katragkou A","year":"2014","unstructured":"Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses?. Clin Microbiol Infect. 2014, 20:74-81. 10.1111\/1469-0691.12466","journal-title":"Clin Microbiol Infect"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: an update","volume":"6","author":"Skiada A","year":"2020","unstructured":"Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel). 2020, 6:265. 10.3390\/jof6040265","journal-title":"J Fungi (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit929","article-title":"The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?","volume":"58","author":"Legouge C","year":"2014","unstructured":"Legouge C, Caillot D, Chretien ML, et al.. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?. Clin Infect Dis. 2014, 58:672-8. 10.1093\/cid\/cit929","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos G","year":"2005","unstructured":"Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005, 41:60-6. 10.1086\/430710","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myx017","article-title":"Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases","volume":"56","author":"Corzo-Le\u00f3n DE","year":"2018","unstructured":"Corzo-Le\u00f3n DE, Chora-Hern\u00e1ndez LD, Rodr\u00edguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018, 56:29-43. 10.1093\/mmy\/myx017","journal-title":"Med Mycol"},{"key":"ref25","unstructured":"Isavuconazole SmPC. (2020). Accessed. July 28, 2020: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002734\/WC500196128.pdf."},{"key":"ref26","unstructured":"Cresemba prescribing information. (2015). Accessed. August 5, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lbl.pdf."},{"key":"ref27","unstructured":"CRESEMBA capsules and solution for infusion. (2020). https.\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=15034."},{"key":"ref28","unstructured":"Amphotericin B SmPC. (2020). Accessed. July 28, 2020: https:\/\/www.medicines.org.uk\/emc\/medicine\/1236."},{"key":"ref29","unstructured":"AmBisome\u00ae (amphotericin B) liposome for injection. (2020). Accessed. August 5, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050740s016lbl.pdf."},{"key":"ref30","unstructured":"Fungisome. Liposomal amphotericin B. (2020). Accessed. August 21, 2020: https:\/\/www.lifecareinnovations.com\/fungisome.php."},{"key":"ref31","unstructured":"National list of essential medicines. (2015). Accessed. August 21, 2020: https:\/\/www.nhp.gov.in\/NHPfiles\/NLEM%2C%202015.pdf."},{"key":"ref32","unstructured":"CANCIDAS 50 mg (formerly Caspofungin MSD) powder for concentrate for solution for infusion. (2019). Accessed. August 5, 2020: https:\/\/www.medicines.org.uk\/emc\/product\/2226."},{"key":"ref33","unstructured":"CANCIDAS\u00ae (caspofungin acetate). (2020). Accessed. August 5, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/21227s015lbl.pdf."},{"key":"ref34","unstructured":"New drugs approved by CDSCO. (2020). Accessed. August 21, 2020: https:\/\/cdscoonline.gov.in\/CDSCO\/Drugs."},{"key":"ref35","unstructured":"Posaconazole label. (2015). Accessed. August 5, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf."},{"key":"ref36","unstructured":"Noxafil. Summary of product characteristics. (2020). Accessed. July 28, 2020: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/noxafil-epar-product-information_en.pdf."},{"key":"ref37","unstructured":"Voriconazole. Summary of product characteristics. (2005). Accessed. July 28, 2020: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2005\/200503299473\/anx_9473_en.pdf."},{"key":"ref38","unstructured":"Voriconazole label. (2015). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021266s038,021267s047,021630s028lbl.pdf."},{"key":"ref39","unstructured":"Voriconazole tablets I.P. and voriconazole powder for solution for infusion I.P. VFEND. (2019). https.\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=15028."},{"key":"ref40","unstructured":"Fungizone 50mg powder for sterile concentrate. (2019). Accessed. August 5, 2020: https:\/\/www.medicines.org.uk\/emc\/product\/10716\/smpc."},{"key":"ref41","unstructured":"Drug information. Amphotericin B. (2017). Accessed. April 8, 2021: https:\/\/aidsinfo.nih.gov\/drugs\/6\/amphotericin-b\/117\/professional."},{"key":"ref42","unstructured":"Abelcet lipid complex 5 mg\/mL concentrate for dispersion for infusion. (2020). Accessed. August 5, 2020: https:\/\/www.medthority.com\/drugs\/j-antiinfectives-for-systemic-use\/j02\/j02a\/j02aa\/j02aa01\/abelcet-5mgml-concentrate-f...."},{"key":"ref43","unstructured":"Amphotericin B lipid complex injection. (2017). Accessed. August 5, 2020: https:\/\/medlineplus.gov\/druginfo\/meds\/a601132.html."},{"key":"ref44","unstructured":"Itraconazole 100 mg capsules. (2020). Accessed. August 5, 2020: https:\/\/www.medicines.org.uk\/emc\/product\/7297\/smpc#gref."},{"key":"ref45","unstructured":"Itraconazole label. (2012). Accessed. August 5, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020083s048s049s050lbl.pdf."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4103\/2141-9248.113669","article-title":"Fungal infections in intensive care unit: challenges in diagnosis and management","volume":"3","author":"Bajwa S","year":"2013","unstructured":"Bajwa S, Kulshrestha A. Fungal infections in intensive care unit: challenges in diagnosis and management. Ann Med Health Sci Res. 2013, 3:238-44. 10.4103\/2141-9248.113669","journal-title":"Ann Med Health Sci Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives","volume":"30","author":"Brunet K","year":"2020","unstructured":"Brunet K, Rammaert B. Mucormycosis treatment: recommendations, latest advances, and perspectives. J Mycol Med. 2020, 30:101007. 10.1016\/j.mycmed.2020.101007","journal-title":"J Mycol Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely OA","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, et al.. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019, 19:e405-21. 10.1016\/S1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2018.04.006","article-title":"Mold infections in solid organ transplant recipients","volume":"32","author":"Lemonovich TL","year":"2018","unstructured":"Lemonovich TL. Mold infections in solid organ transplant recipients. Infect Dis Clin North Am. 2018, 32:687-701. 10.1016\/j.idc.2018.04.006","journal-title":"Infect Dis Clin North Am"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana L","year":"2020","unstructured":"Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, Hakki M. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020, 70:723-30. 10.1093\/cid\/ciz282","journal-title":"Clin Infect Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.02.006","article-title":"Fungal infections of the stem cell transplant recipient and hematologic malignancy patients","volume":"33","author":"Bays DJ","year":"2019","unstructured":"Bays DJ, Thompson GR 3rd. Fungal infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin North Am. 2019, 33:545-66. 10.1016\/j.idc.2019.02.006","journal-title":"Infect Dis Clin North Am"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot F","year":"2017","unstructured":"Tissot F, Agrawal S, Pagano L, et al.. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017, 102:433-44. 10.3324\/haematol.2016.152900","journal-title":"Haematologica"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1778-z","article-title":"Immunoparalysis as a cause for invasive aspergillosis?","volume":"29","author":"Hartemink KJ","year":"2003","unstructured":"Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immunoparalysis as a cause for invasive aspergillosis?. Intensive Care Med. 2003, 29:2068-71. 10.1007\/s00134-003-1778-z","journal-title":"Intensive Care Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The changing epidemiology of invasive fungal infections","author":"Enoch DA","year":"2017","unstructured":"Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Human Fungal Pathogen Identification. Methods in Molecular Biology. Lion T (ed): Humana Press, New York, NY; 2017. 10.1007\/978-1-4939-6515-1_2"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada A","year":"2018","unstructured":"Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018, 56:93-101. 10.1093\/mmy\/myx101","journal-title":"Med Mycol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore JP","year":"2016","unstructured":"Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Med Mycol. 2016, 54:223-31. 10.1093\/mmy\/myv111","journal-title":"Med Mycol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-021-00528-2","article-title":"Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature","volume":"186","author":"Garg D","year":"2021","unstructured":"Garg D, Muthu V, Sehgal IS, et al.. Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021, 186:289-98. 10.1007\/s11046-021-00528-2","journal-title":"Mycopathologia"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2021.04.012","article-title":"Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review","volume":"113","author":"Chong WH","year":"2021","unstructured":"Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect. 2021, 113:115-29. 10.1016\/j.jhin.2021.04.012","journal-title":"J Hosp Infect"},{"key":"ref59","article-title":"Post COVID-19 mucormycosis - from the frying pan into the fire","volume":"69","author":"Soman R","year":"2021","unstructured":"Soman R, Sunavala A. Post COVID-19 mucormycosis - from the frying pan into the fire. J Assoc Physicians India. 2021, 69:13-4.","journal-title":"J Assoc Physicians India"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler P","year":"2021","unstructured":"Koehler P, Bassetti M, Chakrabarti A, et al.. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021, 21:e149-62. 10.1016\/S1473-3099(20)30847-1","journal-title":"Lancet Infect Dis"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3201\/eid2901.220926","article-title":"Multicenter case-control study of COVID-19-associated mucormycosis outbreak, India","volume":"29","author":"Muthu V","year":"2023","unstructured":"Muthu V, Agarwal R, Rudramurthy SM, et al.. Multicenter case-control study of COVID-19-associated mucormycosis outbreak, India. Emerg Infect Dis. 2023, 29:8-19. 10.3201\/eid2901.220926","journal-title":"Emerg Infect Dis"},{"key":"ref62","unstructured":"European Medical Agency. Voriconazole. Summary of product characteristics. (2021). Accessed. March 26, 2021: https:\/\/ec.europa.eu\/health\/documents\/communityregister\/2005\/200503299473\/anx_9473_en.pdf."},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0271","article-title":"Invasive fungal infection","volume":"116","author":"von Lilienfeld-Toal M","year":"2019","unstructured":"von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O. Invasive fungal infection. Dtsch Arztebl Int. 2019, 116:271-8. 10.3238\/arztebl.2019.0271","journal-title":"Dtsch Arztebl Int"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann R","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017, 45:737-79. 10.1007\/s15010-017-1042-z","journal-title":"Infection"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-13","article-title":"Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies","volume":"57","author":"Hoenigl M","year":"2013","unstructured":"Hoenigl M, Duettmann W, Raggam RB, et al.. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013, 57:3262-7. 10.1128\/AAC.00251-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00884-15","article-title":"In vitro study of the variable effects of proton pump inhibitors on voriconazole","volume":"59","author":"Niece KL","year":"2015","unstructured":"Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015, 59:5548-54. 10.1128\/AAC.00884-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan V","year":"2007","unstructured":"Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007, 45:1610-7. 10.1086\/523576","journal-title":"Clin Infect Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap YG","year":"2003","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003, 89:1363-72. 10.1136\/heart.89.11.1363","journal-title":"Heart"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0235-8","article-title":"Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study","volume":"16","author":"Yi WM","year":"2017","unstructured":"Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, Kiser TH. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017, 16:60. 10.1186\/s12941-017-0235-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers BG","year":"2016","unstructured":"Dekkers BG, Bakker M, van der Elst KC, Sturkenboom MG, Veringa A, Span LF, Alffenaar JC. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016, 10:51-61. 10.1007\/s12281-016-0255-4","journal-title":"Curr Fungal Infect Rep"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee HR","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014, 69:1162-76. 10.1093\/jac\/dkt508","journal-title":"J Antimicrob Chemother"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2011.01.027","article-title":"Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition","volume":"202","author":"Dvorak Z","year":"2011","unstructured":"Dvorak Z. Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol Lett. 2011, 202:129-32. 10.1016\/j.toxlet.2011.01.027","journal-title":"Toxicol Lett"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2018.12.001","article-title":"Fungal infections in solid organ transplantation: an update on diagnosis and treatment","volume":"33","author":"Kabir V","year":"2019","unstructured":"Kabir V, Maertens J, Kuypers D. Fungal infections in solid organ transplantation: an update on diagnosis and treatment. Transplant Rev (Orlando). 2019, 33:77-86. 10.1016\/j.trre.2018.12.001","journal-title":"Transplant Rev (Orlando)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth M","year":"2020","unstructured":"Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: mechanism of action, clinical efficacy, and resistance. J Fungi (Basel). 2020, 6:324. 10.3390\/jof6040324","journal-title":"J Fungi (Basel)"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens JA","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al.. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016, 387:760-9. 10.1016\/S0140-6736(15)01159-9","journal-title":"Lancet"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John J","year":"2019","unstructured":"John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019, 15:881-95. 10.1080\/17425255.2019.1671971","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann AJ","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al.. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018, 24:e1-38. 10.1016\/j.cmi.2018.01.002","journal-title":"Clin Microbiol Infect"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: a review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley M","year":"2016","unstructured":"Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016, 76:1647-57. 10.1007\/s40265-016-0652-6","journal-title":"Drugs"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson TF","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al.. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016, 63:e1-60. 10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/128571-the-fragile-patient-considerations-in-the-management-of-invasive-mould-infections-imis-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:12Z","timestamp":1707508572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/128571-the-fragile-patient-considerations-in-the-management-of-invasive-mould-infections-imis-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":79,"URL":"https:\/\/doi.org\/10.7759\/cureus.38085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,24]]}}}